Emotional dysregulation

Mindpath Health releases Daddy Issues: Understanding Attachment Trauma

Retrieved on: 
Mercoledì, Febbraio 21, 2024

A psychological name for daddy issues: attachment trauma

Key Points: 
  • A psychological name for daddy issues: attachment trauma
    Clearly, 'daddy issues' is not a clinical term, and you won't find it in the DSM.
  • At its core, 'daddy issues' is a label for something very clinical: attachment trauma.
  • Like many forms of trauma, attachment trauma can have real effects on your mental health .
  • Attachment trauma, or the effects of inconsistent or abusive parenting, shows up in several different insecure attachment styles developed by psychologist John Bowlby .

XRHealth Introduces Full PTSD Package using XR Therapy and Opens a Center Focusing on XR Trauma Treatments in Tel Aviv

Retrieved on: 
Mercoledì, Dicembre 6, 2023

BOSTON, Dec. 6, 2023 /PRNewswire/ -- XRHealth, a leading healthcare platform in spatial computing, announces today that they are releasing a full PTSD package for XR therapy. The offering will include practices in mindfulness, art therapy, cognitive behavioral therapy, exposure therapy, and EMDR. Due to the current need, XRHealth also opened a PTSD center in Tel Aviv, Israel, where clinical therapy and training in spatial computing treatment for trauma is done which will become a world hub for the use of XR to treat trauma.

Key Points: 
  • The offering will include practices in mindfulness, art therapy, cognitive behavioral therapy, exposure therapy, and EMDR.
  • Due to the current need, XRHealth also opened a PTSD center in Tel Aviv, Israel, where clinical therapy and training in spatial computing treatment for trauma is done which will become a world hub for the use of XR to treat trauma.
  • The release of the PTSD package comes after the release of hostages and terrorist attacks in Israel.
  • XRHealth will be showcasing the PTSD package at CES on Jan 9-12 at the Venetian Expo, Halls A-D at the AARP booth #53623.

Global ATR Protein Inhibitors Market Set to Revolutionize Cancer Treatment and Expand into Neurodegenerative and Infectious Diseases - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Novembre 8, 2023

A promising frontier in cancer pharmaceutical research, the inhibition of Ataxia telangiectasia and Rad3 related kinase (ATR kinase) is poised to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.

Key Points: 
  • A promising frontier in cancer pharmaceutical research, the inhibition of Ataxia telangiectasia and Rad3 related kinase (ATR kinase) is poised to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.
  • Pipeline Analysis: The report offers insights into the global ATR protein inhibitors clinical pipeline, categorized by company, indication, and phase.
  • Development Trends: ATR inhibitors are expanding their scope to include neurodegenerative diseases and viral infections, opening new avenues for treatment.
  • This innovative approach to targeting DNA damage response pathways has the potential to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.

Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting

Retrieved on: 
Giovedì, Ottobre 19, 2023

LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced e-poster presentations at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting, taking place November 5-7, 2023, in Seoul, Korea.

Key Points: 
  • LOS ANGELES, Oct. 19, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced e-poster presentations at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting, taking place November 5-7, 2023, in Seoul, Korea.
  • Abstract and e-poster presentation details are below:
    This is a Phase 2 open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus and letrozole in patients with advanced or recurrent endometrioid endometrial carcinoma, exploring the potential for this combination to produce additive anti-tumor activity in patients with endometrioid-type endometrial carcinoma (EEC)
    Dysregulation of mTOR signaling is implicated in the pathology of EEC, in which >80% harbor PTEN or PI3K/AKT/mTOR pathway alterations
    In preclinical models, intravenous nab-sirolimus demonstrates significantly higher tumor growth inhibition, intra-tumoral drug accumulation, and greater mTOR target suppression compared with oral inhibitors
    An encore presentation titled, "Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION1)" will be displayed as an e-poster during the meeting.

Advocacy Organizations Applaud Governor Newsom on Signing AB1412 to Eliminate Borderline Personality Disorder Stigma

Retrieved on: 
Giovedì, Ottobre 19, 2023

This represents a victory for BPD clients and advocacy organizations including the bill's sponsor, California Council of Community Behavioral Health Agencies (CBHA), Emotions Matter, and the National Education Alliance for Borderline Personality Disorder.

Key Points: 
  • This represents a victory for BPD clients and advocacy organizations including the bill's sponsor, California Council of Community Behavioral Health Agencies (CBHA), Emotions Matter, and the National Education Alliance for Borderline Personality Disorder.
  • Approximately 1.6% of the U. S. population is affected by borderline personality disorder (BPD), a highly stigmatized mental illness characterized by emotional dysregulation, self-harm and suicidality.
  • "Passing AB1412 demonstrates the power of grassroots advocacy to engage in legislative efforts to increase BPD education," commented Abby Ingber, Executive Director of the National Education Alliance for Borderline Personality Disorder.
  • The National Education Alliance for Borderline Personality Disorder is a 501c3 non-profit organization to provide education, decrease stigma, promote research, and enhance the quality of life of those affected by BPD.

Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy

Retrieved on: 
Mercoledì, Settembre 27, 2023

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, has entered into an exclusive license, collaboration and supply agreement with Everads Therapy, Ltd (“Everads”) to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads' suprachoroidal delivery device. Everads is a private biotech company that has developed a novel technology enabling targeted delivery of therapies to the retina via the suprachoroidal space, an anatomical compartment located between the sclera and choroid that traverses the circumference of the posterior segment of the eye. Suprachoroidal delivery is an emerging, non-surgical route of administration in ophthalmology. Specifically in delivery of gene therapy, this route of administration offers the potential to enhance the efficiency of gene therapy delivery to the retina while minimizing intraocular inflammation.

Key Points: 
  • Specifically in delivery of gene therapy, this route of administration offers the potential to enhance the efficiency of gene therapy delivery to the retina while minimizing intraocular inflammation.
  • The transaction enables Kriya’s access to Everads’ suprachoroidal delivery technology to deliver multiple prespecified gene therapy product candidates for several ophthalmic diseases, including those involving the complement cascade.
  • “I am quite optimistic and convinced that innovative therapies will continue to improve the lives of people with geographic atrophy and other serious ophthalmic diseases.
  • A gene therapy targeting the C3 and C5 pathways delivered by a suprachoroidal injection may be a significant improvement in the treatment of geographic atrophy.”

If your kid is home sick from school, is unlimited screen time OK?

Retrieved on: 
Martedì, Luglio 18, 2023

Managing a child’s screen time when they’re home sick from school has taken on a whole new dimension.

Key Points: 
  • Managing a child’s screen time when they’re home sick from school has taken on a whole new dimension.
  • For many parents, the challenge of juggling work and caring for a sick child at home inevitably leads to more TV or iPad.

Illness should not automatically equal unlimited screens

    • The answer depends on several factors and understanding these elements can help parents manage their child’s screen time effectively and healthily.
    • Still, we should also try to avoid a pattern where every minor illness is seen as a gateway to endless screen time.
    • Over time, this could lead to a situation where children might exaggerate or even feign symptoms of illness to gain extra screen time.

How old is your child?

    • The Australian screen time guidelines for young children and toddlers are less than those for older children.
    • This means more guidance and support is needed to manage younger children’s use of screens.
    • There are also continued concerns about the mental health impacts of young people’s social media use.

How sick is your child?

    • Some illnesses, such as high fever or flu, necessitate ample rest to aid recovery.
    • The stimulating effects of screen light can disrupt a child’s sleep, hindering the rest and recovery process.

What are the pre-existing rules in your house?

    • Having a baseline – even if it is more generous – makes some screen time limits during a sick day an expected norm.
    • Maintaining these rules can help prevent a free-for-all scenario, which could complicate matters once the child recovers and needs to readjust to their regular schedule.
    • On the other hand, if there are no pre-existing rules for non-school days, introducing snap strict screen time regulations when a child is unwell may not be the best approach.

Keep an eye on things

    • Consider supporting decisions that help them rest and then switch off after an agreed period.
    • It’s also of course essential to distinguish between entertainment screen use and schoolwork that must be completed on a computer or tablet.
    • Jordy Kaufman has received funding from the Australian Department of Education and Training to research children’s use of technology for education.

NIH STUDY SUGGESTS MATERNAL INFLAMMATION RISK FACTORS ASSOCIATED WITH CHILDREN'S BEHAVIORAL AND EMOTIONAL REGULATION

Retrieved on: 
Lunedì, Luglio 17, 2023

DURHAM, N.C., July 17, 2023 /PRNewswire/ -- Maternal inflammation risk factors may be associated with dysregulation in children, according to a study funded by the Environmental influences on Child Health Outcomes (ECHO) Program at the National Institutes of Health.

Key Points: 
  • DURHAM, N.C., July 17, 2023 /PRNewswire/ -- Maternal inflammation risk factors may be associated with dysregulation in children, according to a study funded by the Environmental influences on Child Health Outcomes (ECHO) Program at the National Institutes of Health.
  • While inflammation is a normal bodily response to injury or infection, ECHO investigators wanted to learn whether factors linked to inflammation during pregnancy might be associated with dysregulation in children.
  • More youth with dysregulation (35%) were born to mothers with prenatal infections compared with 28% of youth without dysregulation.
  • Other maternal factors studied, including being overweight before pregnancy, attaining less education, and smoking during pregnancy, were associated with higher likelihoods of childhood dysregulation.

ADHD: inattention and hyperactivity have been the focus of research – but emotional problems may be the missing link

Retrieved on: 
Sabato, Giugno 10, 2023

ADHD is diagnosed using criteria from a document called DSM-5, which include symptoms of inattention, hyperactivity and impulsivity.

Key Points: 
  • ADHD is diagnosed using criteria from a document called DSM-5, which include symptoms of inattention, hyperactivity and impulsivity.
  • But it is becoming increasingly clear to researchers that the condition also comes with self-control problems, affecting the ability to regulate emotions.
  • For example, 2.1% of children with a diagnosis of ADHD also have a mood disorder, such as depression, while 27.4% have an anxiety disorder.
  • Children with anxiety and depression symptoms only exhibited those deficits if they also had problems with attention.
  • So it seems that one possible route to helping children with ADHD or mood disorders with cognitive development is to focus on improving their attention.

Treatments

    • Methylphenidate roughly works by increasing three chemicals in the brain: dopamine, serotonin and noradrenaline.
    • Dopamine can improve attention, learning, working memory and motivation, while noradrenaline reduces impulsivity and boosts attention.
    • This research suggests that cognitive control, which is associated with frontal areas, can be improved by methylphenidate.
    • This should be offered to children with ADHD, in conjunction with pharmacological treatments.

ADHD on the rise

    • The number of ADHD diagnoses are rising across the world, and so are prescriptions of methylphenidate.
    • In the UK, a study estimated that the use of ADHD medications has increased by almost 800% from 2000 to 2015.
    • It may be that the prevalence of ADHD will increase even more in the future as coping strategies become less effective and people seek help and ultimately receive a diagnosis.
    • The more we learn about brain basis of ADHD, the easier it will get to treat.

Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

Retrieved on: 
Mercoledì, Marzo 22, 2023

Brain penetrant inhibitors of TYK2/JAK1 have the potential to bring this validated immune target to brain disorders.

Key Points: 
  • Brain penetrant inhibitors of TYK2/JAK1 have the potential to bring this validated immune target to brain disorders.
  • There are currently no brain penetrant, selective, dual TYK2/JAK1 inhibitors approved for brain disorders.
  • We have delivered what we believe is a best-in-class dual TYK2/JAK1 molecule and the team at Biohaven has the clinical development expertise to explore its utility in brain disorders.
  • We are excited to work with Chris and the team at Highlightll to advance this novel and highly differentiated dual TYK2/JAK1 inhibitor in the treatment of brain disorders."